Current and emerging strategies for the management of sarcoidosis

Abstract

Sarcoidosis is a systemic inflammatory disorder of unknown etiology. Although any organ may be involved, the lungs are most frequently affected. The clinical course of the disease is highly variable, with up to two-thirds of untreated patients experiencing spontaneous remission within 12-24 months of onset of symptoms. When therapy is required, corticosteroids are considered standard, but studies demonstrating their ability to modify the long-term outcome in this disease are lacking. Often, the myriad of adverse side effects of corticosteroids necessitate the addition of immunosuppressants, cytotoxic agents or biologic therapies to maintain disease remission. Unfortunately, optimal therapeutic regimens have not been described. Patients who do not respond to therapy often experience progressive fibrotic changes and end-organ damage, which ultimately may result in significant morbidity or death. Agents commonly used to treat patients with sarcoidosis and emerging therapeutic options are discussed.

An Unusual Entity of Sarcoidosis: Acute Parotitis

“…However, medical therapy is not mandated for sarcoidosis because of regression spontaneously. 3,6,8 In our case, patient was treated by prednisolone 2 mg/ kg/day in a 2 years and the severity of his symptoms decreased following treatment, prednisolone dose was reduced to 2 mg/ day.…”

“…[5][6][7][8] Parotid gland affecting cause variable clinic presentation between acute parotitis and diffuse parotid enlargement due to chronic inflammation. It can cause sicca like-symptom in patients.…”

Sarcoidosis infantil. Un caso clínico infrecuente

“…Otros inmunosupresores, en especial el metotrexato en dosis bajas, se utilizaron para tratar a pacientes adultos con sarcoidosis a fin de moderar el uso de corticosteroides. 10 N o s o t r o s t r a t a m o s a l a p a c i e n t e c o n corticosteroides y metotrexato hasta la resolución de los síntomas. La dosis de prednisolona se redujo gradualmente hasta 2 mg/día en un año.…”

An unusual case of childhood sarcoidosis

“…Other immunosuppressive agents, especially low-dose methotrexate (MTX) has been used to treat adult patients with sarcoidosis as a steroidsparing agent. 10 We treated our patient with CS and MTX and she became asymptomatic under this therapy. Prednisolone dose was reduced gradually to 2 mg/day in a year.…”